The Serum Concentrations of Chemokine CXCL12 and Its Specific Receptor CXCR4 in Patients with Esophageal Cancer

Table 2

Serum levels of proteins tested in patients with esophageal cancer in comparison with healthy controls.

⁢Group tested		CXCL12; (ng/mL)	CXCR4; (ng/mL)	CEA; (ng/mL)	SCC-Ag; (ng/mL)	CRP; (ng/mL)
Control group ()	Median; (range)	0.865; (0.105–4.297)	0.932; (0.079–2.879)	1.230; (0.500–4.540)	1.000; (0.600–2.500)	1.050; (0.200–10.900)
Esophageal cancer (); Total group	Median; (range); (EC versus healthy controls)	1.277; (0.108–3.106)	0.443; (0.049–1.516)	2.220; (0.500–65.060)	1.200; (0.400–8.100); 0.567	6.500; (0.200–217.600)
Adenocarcinoma of esophagus (AC) ()	Median; (range); (AC versus healthy controls)	1.118; (0.108–2.697); 0.216	0.403; (0.049–1.516)	1.955; (0.500–46.550)	0.800; (0.400–2.200); 0.154	2.800; (0.200–46.800)
Squamous cell cancer of esophagus (ESCC) ()	Median; (range); (ESCC versus healthy controls); (AC versus ESCC)	1.501; (0.380–3.106); 0.562	0.534; (0.076–1.466); 0.146; 0.168	2.250; (0.500–65.060); 0.904	1.400; (0.500–8.100)	14.900; (0.200–217.600)

Statistically significant when .